Advaxis, Incorporated


Based in North Brunswick, New Jersey, Advaxis is developing proprietary Listeria monocytogenes (Lm) cancer vaccines based on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis’ scientific advisory board. Advaxis is developing attenuated live Lm vaccines that deliver engineered tumor antigens, which stimulate multiple simultaneous immunological mechanisms to fight cancer.

Tuesday, March 2, 2010

Advaxis Management Discusses FY2009 on Results Call

For information about the results call: Telephone: Dial-in number: (218) 862-6403 | Access Code: 198209 Playback available until June 25, 2010 until 1800 EST

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, conducted its fiscal year end results conference call yesterday. Following is a summary


  • Efforts to maximize shareholder value by demonstrating safety and efficacy of Advaxis’ lead, drug candidate ADXS11-001 – the overall development program for the Company’s proprietary live, attenuated Listeria immunotherapeutic agents for the treatment of cancer and infectious diseases
  • Efforts to complete construct licensing post Phase II research, which may result in earlier capital returns
  • Lowering corporate risk and maintaining corporate focus through strategic collaborations with recognized sites of excellence such as the City of Hope, the Roswell Park Cancer Institute, the National Cancer Institute (NCI), the University of Pittsburgh and Cancer Research – UK (CRUK)
  • Pre-clinical development of ADXS31-142 (prostate cancer construct) and ADXS31-164 (breast cancer construct) is close to completion and identification of academic clinical partners to initiate Phase I studies for both agents has begun
  • Currently announced Advaxis clinical trials will have approximately 350 patients receiving in the aggregate with a overall cost to the Company of about $10 million
  • Available funding includes more than $3.5 million in cash of the agreed upon $5.0 million funding instrument with Optimus Life Science Capital Partners, announced in June 2009
  • The current short-term debt program in its final weeks; whereby, approximately $3.4 million was raised and roughly $900,000 repaid, with interest, to the debt holders.
Posted by at